CDC2 gene amplification correlates with increased survival in glioblastoma multiforme (GBM) and astrocytoma WHO grades II-III, but not in oligodendroglioma WHO grades II-III. This evidence concerns the gene CDK1 and astrocytoma (excluding glioblastoma).